• Earlier this week, Viking Therapeutics appointed Hubert C. Chen, M.D., as chief medical officer, tasking him with leading clinical development, medical, and regulatory affairs as its metabolic and endocrine disorder programs advance.
• Dr. Chen’s track record in securing drug approvals and crafting regulatory strategies for complex therapies adds experienced oversight at a time when Viking’s obesity-focused pipeline is entering critical late-stage trials.
• We’ll now examine how Dr. Chen’s appointment as chief medical officer could reshape Viking Therapeutics’ existing investment narrative around VK2735.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you have to believe VK2735 can successfully clear late stage trials and become a meaningful obesity treatment across both injectable and oral formats. The near term catalyst remains the Phase III VANQUISH readouts and upcoming oral Phase III launch, while the key risk is that trial delays, failures, or safety issues could extend losses. Dr. Chen’s appointment strengthens clinical and regulatory leadership but does not materially change those near term catalysts or core risks.

The most relevant recent update is Viking’s completion of enrollment in the Phase III VANQUISH-2 trial for injectable VK2735, with key data expected later this year. Dr. Chen’s background in obesity, GLP-1 and GIP programs, and prior regulatory approvals aligns directly with this pivotal phase of development, as his oversight could influence trial execution quality and regulatory engagement around VK2735 just as the program approaches multiple data and filing milestones.

Yet even with experienced new leadership, the risk that high R&D spend and ongoing net losses pressure Viking’s balance sheet is something investors should be aware of...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This implies an earnings increase of about $372 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 223% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most optimistic analysts leaned heavily on catalysts like VANQUISH-1’s ahead of schedule enrollment and forecast Viking reaching US$497.5 million revenue and US$62.2 million earnings by 2029, so Dr. Chen’s arrival could either reinforce or challenge those expectations as updated trial and regulatory outcomes emerge.

Explore 12 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.